Partnerships
Dewpoint Therapeutics' DPTX8743 to Enter Phase 1/2a Trial Funded by Cancer Research UK
By News Desk ·
Key takeaways
- Cancer Research UK's Centre for Drug Development will fund, sponsor and execute CTA-enabling studies and a Phase 1/2a trial of DPTX8743.
- Dewpoint Therapeutics retains all rights to DPTX8743 and may license the results and intellectual property.
- Cancer Research UK is eligible for downstream milestones and royalties, with no amounts or specific milestones disclosed.
- Dewpoint selected its first MYC condensate modulator development candidate in February 2026.
Cancer Research UK will fund, sponsor and execute a first-in-human Phase 1/2a trial of Dewpoint Therapeutics' DPTX8743, including CTA-enabling studies, the company said in a release covered by TradingView. No agreement value or cost to Dewpoint was disclosed.
How the DPTX8743 Trial Will Run
DPTX8743 is described as a potential first-in-class small molecule modulator of MYC condensates, aimed at a cancer driver the release calls historically undruggable. Cancer Research UK's Centre for Drug Development has agreed to fund, sponsor and execute the CTA-enabling studies and the Phase 1/2a trial. The collaboration is designed to evaluate safety and establish clinical proof of concept across MYC-driven cancers with high unmet need.
Dewpoint keeps all rights to DPTX8743 and may license the results and intellectual property. Cancer Research UK is eligible for downstream milestones and royalties; no amounts or specific milestones were disclosed. The release cites preclinical findings and no human results, and gives no timing or trial start date.
Cancer Research UK has backed a private member's bill requiring annual government reporting on cancer prevention, diagnosis and treatment, BBC reported on November 13, 2026, alongside 64 charities.
Dewpoint's Earlier Pipeline Steps
Dewpoint selected its first-in-class MYC condensate modulator development candidate in February 2026, according to akta.pro company records, extending its oncology pipeline beyond Wnt-driven cancers. The same records show Dewpoint dosed the first patient in a Phase 1a/2a trial of DPTX3186 for advanced Wnt-pathway activated solid tumors, focused on gastric cancer, in February 2026. The records list a Series D financing of $77.2 million in September 2025 and total funding of $367.6 million.
Trial Partnerships Elsewhere
NAMSA and Advanced Medical Solutions announced a preferred partnership on November 9, 2026, consolidating NAMSA's regulatory, testing and clinical services under one partner, PR Newswire reported. Istios Health partnered with Arkansas Renal Group to expand its cardiovascular-kidney-metabolic clinical research network into Arkansas, FinancialContent Business Page reported on November 12, 2026. K-MedHub and the Korea Brain Research Institute signed a cooperation agreement on May 5, Naver reported on November 6, 2026, covering shared non-human primate facilities and joint national R&D planning.